Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio Group

10.58 EUR-3.29 %28/9 17:29
14,615 following

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-3.29 %
-15.09 %
+0.92 %
-30.96 %
-43.59 %
-44.83 %
-37.57 %
-77.32 %
+564.99 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
445.38M EUR
Turnover
1.57M EUR
P/E (adj.) (26e)
15.89
EV/EBIT (adj.) (26e)
18.13
P/B (26e)
1.87
EV/S (26e)
2.91
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
16.50 EUR
Updated
2026-09-23
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-09-23

Latest extensive report

Released: 2025-01-21

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Yeah, you can’t buy subscription rights on a cheese account (equity savings account / osakesäästötili). Had to fight my way through the Nordnet knowledge test only to realize that you can’t buy that Rev with subscription rights for cheese. Caused some degree of pain the question ...
7 hours ago
by Warren Fyffet
6
Buying subscription rights (merkintäoikeudet) is not possible on Nordea’s equity savings account (OST), at least not at the moment. This theoretically drives down the value of subscription rights if buying is blocked while selling is allowed. Can someone wiser explain if this is ...
8 hours ago
by JBulli
6
To answer in the same way; as I understand it, 1,065 shares, meaning 1,065 subscription rights divided by 9 makes 118 full bundles of 9 plus decimals. Then with each bundle you can buy 4 new shares, so 4 x 118 is 472 new shares. Correct me if I misunderstood. I would also understand...
3 hours ago
by Optis
5
(Share price - subscription price) divided by the ratio of 9/4, which is 2.25
8 hours ago
by Sergio
5
To bring a little variety to the Revendedores (Reven) brand hype, a recent scientific article reveals that the vast majority of ophthalmologists apparently have been encouraged to clean measurement probes even though they are disposable. Naturally, this news is not very welcome from...
5 hours ago
by veronmaksaja
4
KL: Kauppalehti: The health tech company Revenio, known for its intraocular pressure meters, began a rights offering on Monday, offering nearly 13 million new shares to its current shareholders. Revenio performed exceptionally well during the coronavirus pandemic when health technology...
3 hours ago
by Alamäki
2
Did I get this right: I own 1065 Revenio shares. I want to use all subscription rights. 1065 (divided by nine) (times four) = 473.3. The amount must be divisible by 9, so can I subscribe to 468 (or 477?) So can I subscribe to 477, or do I have to subscribe to 468? Or something else...
4 hours ago
by Sami Valonen
0
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/11
2026

Interim report Q3'26

Modellportföljen: Revenios vikt stiger i portföljen i och med nyemissionen
Research2026-09-28 09:11 by
Juha Kinnunen, Atte Riikola, Rauli Juva

Modellportföljen: Revenios vikt stiger i portföljen i och med nyemissionen

Modellportföljen utnyttjar alla sina teckningsrätter i Revenio och köpte dessutom 471 rätter, med vilka vi tecknar totalt 756 nya aktier i företagets emission av teckningsrätter till ett pris av 6,19 EUR per aktie.

Revenio Group
Regulatory press release2026-09-25 13:00

The Finnish Financial Supervisory Authority has approved the Finnish language prospectus in relation to Revenio Group Corporation’s rights offering

Revenio Group
Revenio: The process has progressed to the rights issue
Research2026-09-23 09:36 by
Juha Kinnunen

Revenio: The process has progressed to the rights issue

We update Revenio's target price following the detachment of subscription rights.

Revenio Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Revenio: Subscription price fell short of expectations – Mechanical pressure on per-share figures
Analyst Comment2026-09-22 08:23 by
Juha Kinnunen

Revenio: Subscription price fell short of expectations – Mechanical pressure on per-share figures

A lower-than-expected subscription price of EUR 6.19 increases the number of shares and exerts mechanical pressure on per-share estimates.

Revenio Group
Regulatory press release2026-09-21 16:00

Managers' transactions - Bill Östman

Revenio Group
Regulatory press release2026-09-21 16:00

Managers' transactions - Heli Lindfors

Revenio Group
Regulatory press release2026-09-21 16:00

Managers' transactions - Arne Boye Nielsen

Revenio Group
Regulatory press release2026-09-21 16:00

Managers' transactions - Anat Loewenstein

Revenio Group
Regulatory press release2026-09-21 16:00

Managers' transactions - Marc Abitbol

Revenio Group
Regulatory press release2026-09-21 16:00

Changes in Revenio Group Corporation's own shares

Revenio Group
Regulatory press release2026-09-21 16:00

Managers' transactions - Nicklas Hansen

Revenio Group
Regulatory press release2026-09-21 16:00

Managers' transactions - Charles Vilgrain

Revenio Group
Regulatory press release2026-09-21 11:30

INSIDE INFORMATION: Revenio Group Corporation announces the terms and conditions of its fully underwritten rights offering of approximately EUR 80 million

Revenio Group
Revenio's Capital Markets Day: The picture became clearer but not much brighter
Analyst Comment2026-09-16 13:20 by
Juha Kinnunen

Revenio's Capital Markets Day: The picture became clearer but not much brighter

The integration process is likely to take longer than anticipated, as the company is implementing significant measures still in 2028.

Revenio Group
Revenio Group Capital Markets Day 2026
Webcast2026-09-15 13:00

Revenio Group Capital Markets Day 2026

At the Capital Markets Day, the company's key personnel will present an in-depth overview of Revenio's strategy.

Revenio Group
Regulatory press release2026-09-15 08:00

Revenio updates its strategy for 2027–2029 and provides new financial targets for the strategy period

Revenio Group
Regulatory press release2026-09-14 15:30

Composition of Revenio’s Shareholders’ Nomination Board

Revenio Group
Revenio: New iCare IC1000 strengthens core business competitiveness
Analyst Comment2026-09-10 10:58 by
Juha Kinnunen

Revenio: New iCare IC1000 strengthens core business competitiveness

The digital solutions of the new iCare IC1000 tonometer strengthen the company's core business.

Revenio Group
Press release2026-09-10 08:00

iCare IC1000™: Precision Made Effortless

Revenio Group
Revenio Q2'26: Vision to become clearer toward the end of the year
Research2026-09-09 10:55 by
Juha Kinnunen

Revenio Q2'26: Vision to become clearer toward the end of the year

Revenio's Q2 result fell short of our expectations due to a weak period in the core business. Visionix performed roughly as expected in its debut, and its integration appears to be progressing as planned.

Revenio Group